Medicine
Sovaldi 150 mg oral pellets
Sovaldi 150 mg oral pellets is a prescription medicine containing Sofosbuvir for oral use, marketed by Gilead Sciences, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30 °C (86 °F).
Key facts
- Active ingredient (INN)
- Sofosbuvir
- Brand
- Sovaldi
- Strength
- 150 mg
- Dosage form
- Oral pellets
- Route
- Oral
- Packs
- 60 pellet
- Marketing authorisation holder
- Gilead Sciences
- Manufacturer
- Gilead Sciences
- Origin register
- US FDA, United States
- Storage
- Store below 30 °C (86 °F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J05AP08 Sofosbuvir
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 28 August 2019
- Identifiers
- RxCUI 1484916, 1484922, 2203891 +5DailyMed set ID 80beab2c-396e-4a37-a4dc-40fdb62859cfNDC 61958-1504Application NDA212480
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 60 pellet in 1 packet | 61958-1504-1 | Gilead Sciences | 28 August 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Sofosbuvir
Clinical summary
Sofosbuvir is a hepatitis C virus nucleotide analog NS5B polymerase inhibitor indicated for the treatment of adult patients with genotype 1, 2, 3 or 4 chronic HCV infection, among other approved uses. MedsAcross supplies Sofosbuvir for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SofosbuvirFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Sovaldi prescribing information (Gilead Sciences) · U.S. National Library of Medicine, DailyMed
- Sovaldi: European public assessment report (EPAR) · European Medicines Agency
Need Sovaldi 150 mg oral pellets for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.